Page 7 of 8, showing 50 records out of 362 total, starting on record 301, ending on 350
| Publication |
Category |
Year |
|
62. Labrie, F. (2000) Screening and hormonal therapy of localized prostate cancer show major benefits on survival. Cancer J. Sci. Am., 6: S182-S187. |
Prostate Cancer |
2000 |
|
61. Labrie, F. (2000) Prostate cancer and combined androgen blockade at all stages of disease, in: Khayat, D. et Hortobagyi, G.N., eds: Progress in Anti-Cancer Chemotherapy, France, Springer, pp 171-187. |
Prostate Cancer |
2000 |
|
60. Labrie, F., Candas, B. (2000) Androgen blockade in prostate cancer [Letter-to-the-Editor]. Lancet, 356: 341-342. |
Prostate Cancer |
2000 |
|
59. Labrie, F., Luu-The, V., Lin, S.-X., Simard, J., Labrie, C. (2000) Role of 17β-hydroxysteroid dehydrogenases in sex steroid formation in peripheral intracrine tissues. Trends Endocrinol. Metab., 11: 421-427. |
Prostate Cancer |
2000 |
|
58. Labrie, F., Luu-The, V., Lin, S.-X., Simard, J., Labrie, C., El-Alfy, M., Pelletier, G., Bélanger, A. (2000) Intracrinology: role of the family of 17β-hydroxysteroid dehydrogenases in human physiology and disease. J. Mol. Endocrinol., 25: 1-16. |
Prostate Cancer |
2000 |
|
57. Pelletier, G., Labrie, C., Labrie, F. (2000) Localization of oestrogen receptor alpha oestrogen receptor β and androgen receptors in the rat reproductive organs. J. Endocrinol., 165: 359-370. |
Prostate Cancer |
2000 |
|
56. Prostate Cancer Triallist’ Collaborative Group; (2000) Maximum androgen blockade in advanced prostate cancer: an overvierw of the randomised trials. Lancet, 355: 1491-1498. |
Prostate Cancer |
2000 |
|
55. Singh, R., Eeles, R.A., Durocher, F., Simard, J., Edwards, S., Badzioch, M., Kote-Jarai, Z., Teare, D., Fortd, D., Dearnaley, D., Ardern-Jones, A., Murkin, A., Dowe, A., Shearer, R., Kelly, J., Labrie, F., Easton, D., Narod, S.A., Tonin, P.N., Foulkes, W.D. (2000) High risk genes predisposing to prostate cancer development-do they exist? Prostate Cancer Prostatic Dis., 3: 241-247. |
Prostate Cancer |
2000 |
|
54. Xu, J., The International Consortium for Prostate Cancer Genetics. (2000) Combined Analysis of Hereditary Prostate Cancer Linkage to 1q24-25: Results from 772 Hereditary Prostate Cancer Families from the International Consortium for Prostate Cancer Genetics. Am J Hum Genet., 66: 945-57. |
Prostate Cancer |
2000 |
|
53. Crawford, E.D., Miller, G., Labrie, F., Hirano, D., Batuello, J., Globe, M. (2001) Prostate cancer pathology, screening and epidemiology. Reviews in Urology, 3: S2-S10. |
Prostate Cancer |
2001 |
|
52. Gomella, L.G., Labrie, F., Gamito, E.J., Brawer, M.K. (2001) Prostate cancer: risk assessment and diagnostic approaches. Reviews in Urology, 3: S31-S38. |
Prostate Cancer |
2001 |
|
51. Labrie, F. (2001) Le cancer de la prostate: blocage combiné des androgènes comme traitement à tous les stades de la maladie. Oncologie, 3: 3-12. |
Prostate Cancer |
2001 |
|
50. Labrie, F., Candas, B., Cusan, L., Gomez, J.L. (2001) The Laval University screening trial results (Chapter 17), in: Thompson, I.M., Resnick, M.I. et Klein, E.A., eds: Current Clinical Urology, Prostate Cancer Screening, Totowa, NJ, Humana Press Inc., pp 255-279. |
Prostate Cancer |
2001 |
|
49. Labrie, F., Luu-The, V., Labrie, C., Simard, J. (2001) DHEA and its transformation into androgens and estrogens in peripheral target tissues: Intracrinology. Neuroendocrinologie, 22: 185-212. |
Prostate Cancer |
2001 |
|
48. Pelletier, G., Luu-The, V., El Alfy, M., Li, S., Labrie, F. (2001) Immunoelectron microscopic localization of 3β-hydroxysteroid dehydrogenase and type 5 17β-hydroxysteroid dehydrogenase in the human prostate and mammary gland. J. Mol. Endocrinol., 26: 11-19. |
Prostate Cancer |
2001 |
|
47. Roach III, M.J., Thrasher, J.B., Blasko, J., Raben, D., Stone, N., Katz, A., Labrie, F. (2001) Prostatectomy, brachytherapy, intensity modulated radiotherapy, hormonal-radiotherapy, salvae cryosurgery and the role of combined hormonal blokade in the treatment of prostate cancer. Reviews in Urology, 3: S49-S58. |
Prostate Cancer |
2001 |
|
46. Tavtigian, S.V., Simard, J., Teng, D.H.F., Abtin, V., Baumgard, M., Beck, A., Camp, N.J., Carillo, A.R., Chen, Y., Dayananth, P., Desrochers, M., Dumont, M., Farnham, J.M., Frank, D., Frye, C., Ghaffari, S., Gupte, J.S., Hu, R., Iliev, D., Janecki, T., Kort, E.N., Laity, K.E., Leavitt, A., Leblanc, G., McArthur-Morrison, J., Pederson, A., Penn, B., Peterson, K.T., Reid, J.E., Richards, S., Schroeder, M., Smith, R., Snyder, S.C., Swedlund, B., Swensen, J., Thomas, A., Tranchant, M., Woodland, A.-M., Labrie, F., Skolnick, M.H., Neuhausen, S., Rommens, J., Cannon-Albright, L.A. (2001) A candidate prostate cancer susceptibility gene at chromosome 17p. Nat. Genet., 27: 172-180. |
Prostate Cancer |
2001 |
|
45. Labrie, F. (2002) Androgen blockade in prostate cancer in 2002: major benefits on survival in localized disease. Mol Cell Endocrinol, 198: 77-87. |
Prostate Cancer |
2002 |
|
44. Labrie, F. (2002) Endocrine-sensitive cancers of the prostate and breast, in: Baster, J., Melmed, S. et New, M., eds: Genetics in Endocrinology, Lippincott-William and Wilkins, pp 607-661. |
Prostate Cancer |
2002 |
|
43. Labrie, F., Candas, B., Gomez, L.J., Cusan, L. (2002) Can combined androgen blockade provide long term control or possible cure of localized prostate cancer? Urology, 60: 115-119. |
Prostate Cancer |
2002 |
|
42. Labrie, F. (2003) Hormonal therapy in the management of prostate cancer at all stages of the disease, in: Syrigos, K.N., ed. Prostate Cancer: Biology, Diagnosis and Management, London, UK, Oxford University Press, pp 301-314. |
Prostate Cancer |
2003 |
|
41. Labrie, F., Cusan, L., Gomez, J.L., Candas, B., Bélanger, A., Luu-The, V., Simard, J. (2003) De la biologie à la clinique: le décès dû au cancer de la prostate peut-il maintenant être une exception? Médecine/Sciences, 19: 910-19. |
Prostate Cancer |
2003 |
|
40. Simard, J., Dumont, M., Labuda, D., Sinnett, D., Meloche, C., El Alfy, M., Berger, L., Lees, E., Labrie, F., Tavtigian, S.V. (2003) Prostate cancer susceptibility genes: lessons learned and challenges posed. Endocrine Related Cancer, 10: 225-259. |
Prostate Cancer |
2003 |
|
39. Labrie, F. (2004) Current status of endocrine therapy in localized prostate cancer: cure has become a strong possibility. Brazilian J Urol, 30: 3-12. |
Prostate Cancer |
2004 |
|
38. Labrie, F. (2004) Major role of androgen blockade in the success of prostate cancer treatment: cure has become a very good possibility. Prostate Cancer Communication Newsletter, 20: 3-11. |
Prostate Cancer |
2004 |
|
37. Labrie, F. (2004) Medical castration with LHRH agonists: 25 years later with major benefits achieved on survival in prostate cancer. J Androl, 25: 305-313. |
Prostate Cancer |
2004 |
|
36. Labrie, F. (2004) Status of androgen blockade in prostate cancer in 2003, in: Koutsilieris, M. et Labrie, F., eds: Prostate cancer: Understanding the pathophysiology and re-designing a therapeutic approach, Athens, Greece, Paschalidis Medical Publications, pp 157-170. |
Prostate Cancer |
2004 |
|
35. Labrie, F., Candas, B., Cusan, L., Gomez, J.L., Bélanger, A., Brousseau, G., Lévesque, J. (2004) Screening decreases prostate cancer mortality: 11-year follow-up on the 1988 Quebec prospective randomized controlled trial. The Prostate, 59: 311-318. |
Prostate Cancer |
2004 |
|
34. Labrie, F., Candas, B., Cusan, L., Gomez, J.L., Lévesque, J., Chevrette, E., Brousseau, G. (2004) Prostate Cancer Screening and Early Treatment: The Only Possibility for a Major Impact on Survival in Prostate Cancer, in: Labrie, F. et Koutsilieris, M., eds: Prostate Cancer: Understanding the pathophysiology and re-designing a therapeutic approach, Athens, Greece, Paschalidis Medical Publications, pp 67-78. |
Prostate Cancer |
2004 |
|
33. Labrie, F., Cusan, L., Gomez, J., Luu-The, V., Candas, B., Bélanger, A., Labrie, C. (2004) Major impact of hormonal therapy in localized prostate cancer - death can already be an exception. JSBMB, 92: 327-344. |
Prostate Cancer |
2004 |
|
32. Qiu, W., Zhou, M., Labrie, F., Lin, S.-X. (2004) Crystal structures of the multi-specific 17β-hydroxysteroid dehydrogenase type 5: Critical androgen regulation in human peripheral tissues. Mol Endocrinol, 18: 1798-1807. |
Prostate Cancer |
2004 |
|
31. Simard, J., Dumont, M., Soucy, P., Labrie, F., Tavtigian, S.V. (2004) Prostate Cancer Susceptibility Genes, in: Labrie, F. et Koutsilieris, M., eds: Prostate Cancer: Understanding the pathophysiology and re-designing a therapeutic approach, Athens, Greece, Paschalidis Medical Publications, pp 1-38. |
Prostate Cancer |
2004 |
|
30. Labrie, F., Bélanger, A., Luu-The, V., Labrie, C., Simard, J., Cusan, L., Gomez, J., Candas, B. (2005) Gonadotropin-releasing hormone agonists in the treatment of prostate cancer. Endocrine Reviews, 26: 361-379. |
Prostate Cancer |
2005 |
|
29. Labrie, F., Luu-The, V., Bélanger, A., Lin, S.-X., Simard, J., Pelletier, G., Labrie, C. (2005) Is DHEA a hormone? Starling Review. J Endocrinol, 187: 169-196. |
Prostate Cancer |
2005 |
|
28. Candas, B., Labrie, F., Gomez, J.L., Cusan, L., Chevrette, E., Levesque, J., Brousseau, G. (2006) Relationship among initial serum prostate specific antigen, prostate specific antigen progression and prostate cancer detection at repeat screening visits. J Urol, 175: 510-517. |
Prostate Cancer |
2006 |
|
27. Labrie, F. (2006) Keyrole of endocrinology in the victory against prostate cancer. Bull. Cancer, 93: 949-58. |
Prostate Cancer |
2006 |
|
26. Perreira De Jésus, K., Côté, P.L., Cantin, L., Blanchet, J., Labrie, F., Breton, R. (2006) Comparison of crystal structures of human androgen receptor ligand-binding domain complexed with various agonists reveals molecular determinants responsible for binding affinity. Protein Science: a publication of the Protein Society, 15: 987-99. |
Prostate Cancer |
2006 |
|
25. Takase, Y., Lévesque, M.H., Luu-The, V., El-Alfy, M., Labrie, F., Pelletier, G. (2006) Expression of enzymes involved in estrogen metabolism in human prostate. J.Histochem Cytochem., 54: 911-21. |
Prostate Cancer |
2006 |
|
24. Akaza, H., Labrie, F., Namiki, M. (2007) [A way of thinking of a MAB therapy for local/locally advanced prostate cancer: the theory and recent evaluation]. Gan To Kagaku Ryoho. Jpn J Cancer Chemotherapy, 34: 657-669. |
Prostate Cancer |
2007 |
|
23. Cantin, L., Faucher, F., Couture, J.F., de Jésus, K.P., Legrand, P., Ciobanu, L., Fréchette, Y., Labrecque, R., Singh, S.M., Labrie, F., Breton, R. (2007) Structural characterization of the human androgen receptor ligand-binding domain complexed with EM5744, a rationally-designed steroidal ligand bearing a bulky chain directed toward helix 12. J Biol Chem, 282: 30910-9. |
Prostate Cancer |
2007 |
|
22. Labrie, F. (2007) Multiple intracrine hormonal targets in the prostate: oportunities and challenges. BJU Int, 100: 48-51. |
Prostate Cancer |
2007 |
|
21. Levesque, M.H., El-Alfy, M., Berger, L., Labrie, F., Labrie, C. (2007) Evaluation of AIbZIP and Cdc47 as Markers for Human Prostatic Diseases. Urology, 69: 196-201. |
Prostate Cancer |
2007 |
|
20. Roy, J., Breton, R., Martel, C., Labrie, F., Poirier, D. (2007) Chemical synthesis and biological activities of 16α-derivatives of 5α-androstane-3α, 17 β-diol as antiandrogens. Bioorg Med Chem, 15: 3003-3018. |
Prostate Cancer |
2007 |
|
19. Suzuki, K., Nishiyama, T., Hara, N., Yamana, K., Takahashi, K., Labrie, F. (2007) Importance of the intracrine metabolism of adrenal androgens in androgen-dependent prostate cancer. Prostate Cancer Prostatic Dis., 10: 301-6. |
Prostate Cancer |
2007 |
|
18. Swanson, C., Mellström, D., Lorentzon, M., Vanderput, L., Jakobsson, J., Rane, A., Karlsson, M., Ljunggren, O., Smith, U., Eriksson, A.E., Bélanger, A., Labrie, F., Ohlsson, C. (2007) The uridine diphosphate glucuronosyltransferase 2B15 D85Y and 2B17deletion polymorphisms predict the glucuronidation pattern of androgens and fat mass in men. J Clin Endocrinol Metab, 92: 4878-4882. |
Prostate Cancer |
2007 |
|
17. Takase, Y., Luu-The, V., Poisson-Paré, D., Labrie, F., Pelletier, G. (2007) Expression of sulfotransferase 1E1 in human prostate as studied by in situ hybridization and immunocytochemistry. Prostate, 67: 405-409. |
Prostate Cancer |
2007 |
|
16. Tenta, R., Katopodis, H., Chatzïioannou, A., Pilalis, E., Calvo, E., Luu-The, V., Labrie, F., Kolisis, F., Koutsilieris, M. (2007) Microarray analysis of survival pathways in human PC-3 prostate cancer cells. Cancer Genomics Proteomics, 4: 309-18. |
Prostate Cancer |
2007 |
|
15. Vandenput, L., Labrie, F., Mellström, D., Swanson, C., Knutsson, T., Peeker, R., Ljunggren, O., Orwoll, E., Eriksson, A.L., Johnell, O., Damber, J.E., Ohlsson, C. (2007) Serum levels of specific glucuronidated androgen metabolites predict BMD and prostate volume in elderly men. J. of Bone and Mineral Research: The Official Journal of the American Soc. for Bone and Mineral Research, 22: 220-7. |
Prostate Cancer |
2007 |
|
14. Labrie, F. (2008) Preface. Best Pract Res Clin Endocrinol Metab, 22: pp. vii-ix. |
Prostate Cancer |
2008 |
|
13. Luu-The, V., Bélanger, A., Labrie, F. (2008) Androgen biosynthetic pathways in the human prostate. Best Pract Res Clin Endocrinol Metab, 22: 207-221. |
Prostate Cancer |
2008 |